Martín Trinidad, Ojeda Antonio, Martínez Silvestre, Vera Angel
Servicio de Dermatología, Hospital Civil, Complejo Hospitalario Carlos Haya, Málaga, Spain.
Actas Dermosifiliogr. 2005 Dec;96(10):700-2. doi: 10.1016/s0001-7310(05)73162-8.
Lentigo maligna (LM) is considered to be an in-situ stage of lentigo maligna melanoma. Clinically, it presents as a pigmented macule, irregular in shape and tone. 30% to 35% of untreated lentigo malignas can progress into lentigo maligna melanoma. The treatment of choice for this pathology is surgical excision with margins of 0.5 cm. of clinically normal skin around the lesion, or Mohs microsurgery. Imiquimod is a topical immunomodulator that stimulates both acquired and innate immunity. We present the case of a patient with LM, treated with 5% imiquimod cream, with an excellent therapeutic response.
恶性雀斑样痣（LM）被认为是恶性雀斑样痣黑色素瘤的原位阶段。临床上，它表现为色素沉着斑，形状和色调不规则。30%至35%未经治疗的恶性雀斑样痣可进展为恶性雀斑样痣黑色素瘤。这种病理情况的首选治疗方法是手术切除，切除范围包括病变周围0.5厘米临床正常皮肤的边缘，或莫氏显微外科手术。咪喹莫特是一种局部免疫调节剂，可刺激获得性免疫和先天性免疫。我们报告了一例用5%咪喹莫特乳膏治疗的恶性雀斑样痣患者，治疗效果极佳。
